D Grabau

Summary

Affiliation: Lund University
Country: Sweden

Publications

  1. pmc A novel model for Ki67 assessment in breast cancer
    Quinci Romero
    Division of Oncology, Department of Clinical Sciences Lund, Lund University, SE 221 85 Lund, Sweden
    Diagn Pathol 9:118. 2014
  2. ncbi request reprint Completion axillary dissection can safely be omitted in screen detected breast cancer patients with micrometastases. A decade's experience from a single institution
    D Grabau
    Department of Pathology, Skane University Hospital, Lund, Sweden
    Eur J Surg Oncol 39:601-7. 2013
  3. pmc High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer
    Johan Staaf
    Department of Oncology, Clinical Sciences, Lund University, Barngatan 2B, Lund, Sweden
    Breast Cancer Res 12:R25. 2010
  4. pmc The CD44+/CD24- phenotype is enriched in basal-like breast tumors
    Gabriella Honeth
    Department of Oncology, Clinical Sciences, Lund University, Barngatan 2B, SE 221 85 Lund, Sweden
    Breast Cancer Res 10:R53. 2008
  5. pmc Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies
    Quinci Romero
    Department of Oncology, Skane University Hospital, Lund, Sweden
    BMC Cancer 11:341. 2011
  6. ncbi request reprint Analysis of sentinel node biopsy - a single-institution experience supporting the use of serial sectioning and immunohistochemistry for detection of micrometastases by comparing four different histopathological laboratory protocols
    Dorthe Grabau
    Department of Pathology, University Hospital of Lund, Lund, Sweden
    Histopathology 59:129-38. 2011
  7. ncbi request reprint Breast cancer patients with micrometastases only: is a basis provided for tailored treatment?
    D Grabau
    Department of Pathology, Pathologic Cytologic Clinic, University Hospital of Lund, 221 85 Lund, Sweden
    Surg Oncol 17:211-7. 2008
  8. ncbi request reprint The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor
    S Alkner
    Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden
    Ann Oncol 24:1244-52. 2013
  9. ncbi request reprint AIB1 is a predictive factor for tamoxifen response in premenopausal women
    S Alkner
    Departments of Oncology, Clinical Sciences, Lund University, Sweden
    Ann Oncol 21:238-44. 2010
  10. ncbi request reprint Comparison of the oestrogen and progesterone receptor status in primary breast carcinomas as evaluated by immunohistochemistry and immunocytochemistry: a consecutive series of 267 patients
    A M Domanski
    Department of Pathology, Skane University Hospital, Lund, Sweden
    Cytopathology 24:21-5. 2013

Collaborators

  • P Malmstrom
  • Lisa Rydén
  • O Stal
  • Quinci Romero
  • S Alkner
  • M Fernö
  • A M Domanski
  • Signe Borgquist
  • Niklas Loman
  • Johan Staaf
  • Par Ola Bendahl
  • Markus Ringner
  • Ake Borg
  • Gabriella Honeth
  • Pär Ola Bendahl
  • MÃ¥rten Fernö
  • Po Bendahl
  • N Monsef
  • H A Domanski
  • Marie Klintman
  • Carsten Rose
  • Christian Ingvar
  • Haukur Gunnarsson
  • Bjarni A Agnarsson
  • Adalgeir Arason
  • Oskar Th Johannsson
  • Johan Vallon-Christersson
  • Rosa B Barkardottir
  • P O Bendahl
  • Goran Jonsson
  • K Lovgren
  • Sofia K Gruvberger-Saal
  • Mårten Fernö
  • Cecilia Hegardt
  • Lao H Saal
  • Kristina Lövgren

Detail Information

Publications10

  1. pmc A novel model for Ki67 assessment in breast cancer
    Quinci Romero
    Division of Oncology, Department of Clinical Sciences Lund, Lund University, SE 221 85 Lund, Sweden
    Diagn Pathol 9:118. 2014
    ..A lack of consensus regarding Ki67 use in pre-analytical, analytical and post-analytical practice may hinder its formal acceptance in the clinical setting...
  2. ncbi request reprint Completion axillary dissection can safely be omitted in screen detected breast cancer patients with micrometastases. A decade's experience from a single institution
    D Grabau
    Department of Pathology, Skane University Hospital, Lund, Sweden
    Eur J Surg Oncol 39:601-7. 2013
    ..The aim of this retrospective observational study is to determine if the method of detection of early breast cancer is predictive for additional positive nodes in patients with micrometastases in the SNs...
  3. pmc High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer
    Johan Staaf
    Department of Oncology, Clinical Sciences, Lund University, Barngatan 2B, Lund, Sweden
    Breast Cancer Res 12:R25. 2010
    ....
  4. pmc The CD44+/CD24- phenotype is enriched in basal-like breast tumors
    Gabriella Honeth
    Department of Oncology, Clinical Sciences, Lund University, Barngatan 2B, SE 221 85 Lund, Sweden
    Breast Cancer Res 10:R53. 2008
    ..We have explored the prevalence of cells with different CD44/CD24 phenotypes within breast cancer subtypes...
  5. pmc Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies
    Quinci Romero
    Department of Oncology, Skane University Hospital, Lund, Sweden
    BMC Cancer 11:341. 2011
    ..Also, a lack of consensus concerning Ki67 assessment may raise problems in the comparison of neo-adjuvant studies. Thus, the secondary aim was to present a novel model for Ki67 assessment...
  6. ncbi request reprint Analysis of sentinel node biopsy - a single-institution experience supporting the use of serial sectioning and immunohistochemistry for detection of micrometastases by comparing four different histopathological laboratory protocols
    Dorthe Grabau
    Department of Pathology, University Hospital of Lund, Lund, Sweden
    Histopathology 59:129-38. 2011
    ..2 mm/<200 cells) is important for staging of breast cancer patients. The aim of this study was to systematically compare several laboratory protocols used to detect metastases after initial intraoperative frozen section examination...
  7. ncbi request reprint Breast cancer patients with micrometastases only: is a basis provided for tailored treatment?
    D Grabau
    Department of Pathology, Pathologic Cytologic Clinic, University Hospital of Lund, 221 85 Lund, Sweden
    Surg Oncol 17:211-7. 2008
    ..Tailored systemic therapy is also impossible due to lack of a precisely defined target for a feasible therapy...
  8. ncbi request reprint The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor
    S Alkner
    Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden
    Ann Oncol 24:1244-52. 2013
    ..The effect of PAX2 warrants further studies...
  9. ncbi request reprint AIB1 is a predictive factor for tamoxifen response in premenopausal women
    S Alkner
    Departments of Oncology, Clinical Sciences, Lund University, Sweden
    Ann Oncol 21:238-44. 2010
    ..We have further investigated this using a controlled randomised trial of tamoxifen versus control...
  10. ncbi request reprint Comparison of the oestrogen and progesterone receptor status in primary breast carcinomas as evaluated by immunohistochemistry and immunocytochemistry: a consecutive series of 267 patients
    A M Domanski
    Department of Pathology, Skane University Hospital, Lund, Sweden
    Cytopathology 24:21-5. 2013
    ..The aim of this study was to compare the ER and PgR immunocytochemical analysis of fine needle aspiration (FNA) samples with the immunohistochemistry (IHC) of surgical specimens and core biopsies from primary breast cancers...